ARQT sale notice: 39,272 shares reported

Arcutis Biotherapeutics filed a Form 144 notice reporting the intended sale of 39,272 common shares for $997,194.62, dated 03/02/2026.

Rhea-AI Filing Summary

Arcutis Biotherapeutics filed a Form 144 notice reporting the intended sale of 39,272 common shares for $997,194.62, dated 03/02/2026. The filing also lists stock option exercises of 27,052 (06/14/2024) and 12,220 (05/31/2023).

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ARQT disclose in the Form 144 filing?

The filing discloses a notice to sell 39,272 common shares for $997,194.62, dated 03/02/2026. It also lists related stock option exercises of 27,052 and 12,220 on prior exercise dates.

When is the sale notice dated in ARQT's filing?

The Form 144 sale notice is dated 03/02/2026. That date appears next to the reported sale quantities and aggregate dollar amount in the filing excerpt.

How many shares from option exercises are shown in the ARQT excerpt?

The excerpt lists two stock option exercises: 27,052 shares with exercise date 06/14/2024 and 12,220 shares with exercise date 05/31/2023. These figures appear alongside the sale notice entries.

What is the aggregate dollar amount reported for the shares in ARQT's filing?

The filing shows an aggregate amount of $997,194.62 tied to the reported 39,272 common shares. That dollar figure appears in the same row as the share count and the 03/02/2026 date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/02/2026 - 05:59 PM EST Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001416180
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	ARCUTIS BIOTHERAPEUTICS, INC
SEC File Number	001-39186
Address of Issuer	3027 Townsgate Road Suite 300 Westlake Village CALIFORNIA 91361
Phone	805-418-5006
Name of Person for Whose Account the Securities are To Be Sold	Keith Leonard
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Board of Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
common	Merrill 8890 Lyra Dr 5th Flr Columbus OH 43240	39272	997194.62	124033382	03/02/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
common	06/14/2024	Stock option exercise	ARCUTIS BIOTHERAPEUTICS, INC			27052	03/02/2026	Cash
common	05/31/2023	Stock option exercise	ARCUTIS BIOTHERAPEUTICS, INC			12220	03/02/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	03/02/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	11/18/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Keith Leonard
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)